Teladoc Health, Inc. (TDOC) intrinsic value & 10-year financials

Teladoc Health, Inc. (TDOC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 39.9% a year to $2.5B, with an average return on invested capital of -46.7%.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$5.67
Market cap
$999.2M
Revenue (FY2025)
$2.5B
Revenue growth (10-yr CAGR)
39.9%
ROIC (10-yr avg)
-46.7%
Free cash flow (FY2025)
$285.5M

TDOC 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $2.5B -$200.3M -$1.14 $285.5M -10.4% -51.8%
FY2024 $2.6B -$1.0B -$5.87 $282.9M -39.7% -138.9%
FY2023 $2.6B -$220.4M -$1.34 $338.6M -9.6% -18.6%
FY2022 $2.4B -$13.7B -$84.60 $172.8M -567.3% -164.2%
FY2021 $2.0B -$428.8M -$2.73 $185.5M -13.1% -1.7%
FY2020 $1.1B -$485.1M -$5.36 -$57.5M -46.3% -5.4%
FY2019 $553.3M -$98.9M -$1.38 $26.4M -14.5% -13.0%
FY2018 $417.9M -$97.1M — -$8.9M -17.0% -12.0%
FY2017 $233.3M -$106.8M — -$37.1M -32.3% -33.4%
FY2016 $123.2M -$74.2M — -$54.0M -50.9% -27.8%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Teladoc Health, Inc. is a consistent compounder, expanding top-line revenue at 39.9% annually over the past decade.

Teladoc Health, Inc. has historically struggled to out-earn its cost of capital, averaging just -30.4% ROIC.

Teladoc Health, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, Teladoc Health, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-37.87 per share.

TDOC stock: frequently asked questions

What is the intrinsic value of Teladoc Health, Inc. (TDOC) stock?

Graham's formula only works with positive earnings. Teladoc Health, Inc. reported diluted EPS of -$1.14 in fiscal 2025, so no Graham value is shown. The 10-year table shows revenue and cash-flow trends instead.

How fast has Teladoc Health, Inc. grown?

Revenue went from $123.2M in fiscal 2016 to $2.5B in fiscal 2025, a compound annual growth rate of 39.9%. Net income was -$200.3M in fiscal 2025.

Does Teladoc Health, Inc. generate free cash flow?

Teladoc Health, Inc. generated $285.5M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 6 of the last 10 reported years.

What is TDOC's return on invested capital?

Average ROIC over the last 10 fiscal years was -46.7%, and average return on equity was -31.4%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this TDOC data come from?

From Teladoc Health, Inc.'s annual 10-K filings on SEC EDGAR. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar offices & clinics of doctors of medicine stocks